Genmab A/S
GMAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $21,526,000 | $16,474,000 | $14,505,000 | $8,417,000 |
| % Growth | 30.7% | 13.6% | 72.3% | – |
| Cost of Goods Sold | $985,000 | $226,000 | $0 | $0 |
| Gross Profit | $20,541,000 | $16,248,000 | $14,505,000 | $8,417,000 |
| % Margin | 95.4% | 98.6% | 100% | 100% |
| R&D Expenses | $9,748,000 | $7,630,000 | $5,562,000 | $4,181,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3,790,000 | $3,297,000 | $2,676,000 | $1,283,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $300,000 | $0 | $0 | $0 |
| Operating Expenses | $13,838,000 | $10,927,000 | $8,238,000 | $5,464,000 |
| Operating Income | $6,703,000 | $5,321,000 | $6,267,000 | $2,953,000 |
| % Margin | 31.1% | 32.3% | 43.2% | 35.1% |
| Other Income/Exp. Net | $2,461,000 | $316,000 | $678,000 | $965,000 |
| Pre-Tax Income | $9,164,000 | $5,637,000 | $6,945,000 | $3,918,000 |
| Tax Expense | $1,320,000 | $1,285,000 | $1,493,000 | $961,000 |
| Net Income | $7,844,000 | $4,352,000 | $5,452,000 | $2,957,000 |
| % Margin | 36.4% | 26.4% | 37.6% | 35.1% |
| EPS | 12.14 | 6.6 | 8.34 | 4.52 |
| % Growth | 83.9% | -20.9% | 84.5% | – |
| EPS Diluted | 12.14 | 6.6 | 8.26 | 4.48 |
| Weighted Avg Shares Out | 646,340 | 659,190 | 653,870 | 653,960 |
| Weighted Avg Shares Out Dil | 646,330 | 659,150 | 660,100 | 660,460 |
| Supplemental Information | – | – | – | – |
| Interest Income | $995,000 | $939,000 | $324,000 | $197,000 |
| Interest Expense | $120,000 | $27,000 | $21,000 | $13,000 |
| Depreciation & Amortization | $413,000 | $240,000 | $362,000 | $250,000 |
| EBITDA | $9,697,000 | $5,947,000 | $7,346,000 | $4,181,000 |
| % Margin | 45% | 36.1% | 50.6% | 49.7% |